Loading...

Palisade Bio, Inc.

PALINASDAQ
Healthcare
Biotechnology
$1.16
$0.05(4.50%)

Palisade Bio, Inc. (PALI) Company Profile & Overview

Explore Palisade Bio, Inc.’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

Palisade Bio, Inc. (PALI) Company Profile & Overview

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.

SectorHealthcare
IndustryBiotechnology
CEOJ. D. Finley

Contact Information

858 704 4900
5800 Armada Drive, Carlsbad, CA, 92008

Company Facts

8 Employees
IPO DateMar 30, 2007
CountryUS
Actively Trading

Frequently Asked Questions

;